On Tuesday, Beam Therapeutics Inc (NASDAQ: BEAM) was -4.97% drop from the session before settling in for the closing price of $15.30. A 52-week range for BEAM has been $13.52 – $35.25.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 43280.87% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at -3.23%. With a float of $87.89 million, this company’s outstanding shares have now reached $99.84 million.
In an organization with 483 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 74.05%, operating margin of -654.25%, and the pretax margin is -593.06%.
Beam Therapeutics Inc (BEAM) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Beam Therapeutics Inc stocks. The insider ownership of Beam Therapeutics Inc is 11.97%, while institutional ownership is 69.86%. The most recent insider transaction that took place on Apr 01 ’25, was worth 104,122. In this transaction Chief Legal Officer of this company sold 5,674 shares at a rate of $18.35, taking the stock ownership to the 117,294 shares. Before that another transaction happened on Apr 01 ’25, when Company’s CEO sold 30,663 for $18.35, making the entire transaction worth $562,684. This insider now owns 986,249 shares in total.
Beam Therapeutics Inc (BEAM) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.15 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -3.23% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.10% during the next five years compared to -20.88% drop over the previous five years of trading.
Beam Therapeutics Inc (NASDAQ: BEAM) Trading Performance Indicators
You can see what Beam Therapeutics Inc (BEAM) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 4.82. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 22.85.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.58, a number that is poised to hit -1.19 in the next quarter and is forecasted to reach -4.75 in one year’s time.
Technical Analysis of Beam Therapeutics Inc (BEAM)
Let’s dig in a bit further. During the last 5-days, its volume was 3.8 million. That was better than the volume of 1.92 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 11.68%. Additionally, its Average True Range was 2.08.
During the past 100 days, Beam Therapeutics Inc’s (BEAM) raw stochastic average was set at 4.67%, which indicates a significant decrease from 9.22% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 82.92% in the past 14 days, which was higher than the 78.16% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $25.29, while its 200-day Moving Average is $25.50. However, in the short run, Beam Therapeutics Inc’s stock first resistance to watch stands at $15.82. Second resistance stands at $17.11. The third major resistance level sits at $18.02. If the price goes on to break the first support level at $13.62, it is likely to go to the next support level at $12.71. Assuming the price breaks the second support level, the third support level stands at $11.42.
Beam Therapeutics Inc (NASDAQ: BEAM) Key Stats
There are 99,785K outstanding shares of the company, which has a market capitalization of 1.45 billion. As of now, sales total 63,520 K while income totals -376,740 K. Its latest quarter income was 30,070 K while its last quarter net income were -90,350 K.
